Titoli di studio/Ruoli professionali:
1998: Red Cross Nordic United World College, Flekke, Fjaler, Norvegia
Baccellierato Internazionale
2003: Saint Boniface Research Center, Winnipeg, Manitoba, Canada (Università del Manitoba, Università di Bologna)
Laurea in Biotecnologie Farmaceutiche (110 e lode)
2004: Licenza del Collegio Superiore Alma Mater Studiorum
2004: Fondazione Europea per la Genetica - Bologna
Impiegato
2008: Università degli Studi di Torino
Dottorato di Ricerca in Genetica Umana
2009: Unità di Genetica Medica, Pol.Universitario S.Orsola-Malpighi, Università di Bologna
Post-dottorato
2010: Dip. Biochimica e Biologia Molecolare "E.Quagliariello", Università di Bari
Assegnista di Ricerca
2010: Unità di Genetica Medica, Pol.Universitario S.Orsola-Malpighi, Università di Bologna
Ricercatore a Tempo Determinato
2010: Scuola di dottorato in scienze biomediche e oncologia, Università degli Studi di Torino
Docente

Altre esperienze professionali:
2009: Co-organizzatore e faculty dell'EMBO lecture course in mitochondrial medicine, Bologna

2010: Co-organizzatore e faculty del 1° Corso sul Metabolismo Mitocondriale e Cancro, Bologna

Premi:
2011: First Salvatore Venuta Young Investigator Award - Scuola Mediterranea di Oncologia, Roma
2008: Premio Malpighi d'Oro per giovani ricercatori under-30

TRANSMIT " Translational significance of mitochondrial mutations in tumors.

The aim of this collaborative project is to define the determinants of the shift and selection of mitochondrial DNA mutations in cancer and correlate this process with the induction of a benign behavior of the tumor.

PERNO project for Neuro-Oncology:

The project aims at characterizing tumors of the CNS, also in terms of mitochondrial mutations and metabolism.

1.Kurelac I, Lang M, Zuntini R, Calabrese C, Simone D, Vicario S, Santamaria M, Attimonelli M, Romeo G, Gasparre G. (2011) Searching for a needle in the haystack: Comparing six methods to evaluate heteroplasmy in difficult sequence context. Biotech Adv. In press.
2.Guerra F, Kurelac I, Magini P, Cormio A, Santini D, Ceccarelli C, Gasparre G. (2011) Mitochondrial DNA genotyping reveals synchronous nature of simultaneously detected endometrial and ovarian cancers. Gynecol Oncol. In press.
3.Bartoletti-Stella A, Salfi NC, Ceccarelli C, Attimonelli M, Romeo G, Gasparre G. (2011) Mitochondrial DNA mutations in oncocytic adnexal lacrimal glands of the conjunctiva. Arch Ophthalmol 129(5):664-6.
4.Geyer FC, de Biase D, Lambros MB, Ragazzi M, Lopez-Garcia MA, Natrajan R, Mackay A, Kurelac I, Gasparre G, Ashworth A, Eusebi V, Reis-Filho JS, Tallini G. (2011) Genomic profiling of mitochondrion-rich breast carcinoma: chromosomal changes may be relevant for mitochondria accumulation and tumour biology. Breast Cancer Res Treat. In press.
5.Guerra F, Kurelac I, Cormio A, Zuntini R, Amato LB, Ceccarelli C, Santini D, Cormio G, Fracasso F, Selvaggi L, Resta L, Attimonelli M, Gadaleta MN, Gasparre G. (2011) Placing mitochondrial DNA mutations within the progression model of type I endometrial carcinoma. Hum Mol Genet 20(12):2394-405.
6.Kurelac I, Romeo G, Gasparre G. (2011) Mitochondrial metabolism and cancer. Mitochondrion 11(4):635-7.
7.Elachouri G, Vidoni S, Zanna C, Pattyn A, Boukhaddaoui H, Gaget K, Yu-Wai-Man P, Gasparre G, Sarzi E, Delettre C, Olichon A, Loiseau D, Reynier P, Chinnery PF, Rotig A, Carelli V, Hamel CP, Rugolo M, Lenaers G. (2011) OPA1 links human mitochondrial genome maintenance to mtDNA replication and distribution. Genome Res 21(1):12-20.
8.Gasparre G, Romeo G, Rugolo M, Porcelli AM. (2011) Learning from oncocytic tumors: Why choose inefficient mitochondria? Biochim Biophys Acta 1807(6):633-42.
9.Gasparre G, Bonora E, Tallini G, Romeo G. (2010) Molecular features of thyroid oncocytic tumors. Mol Cell Endocrinol 321(1):67-76.
10.Porcelli AM, Ghelli A, Ceccarelli C, Lang M, Cenacchi G, Capristo M, Pennisi LF, Morra I, Ciccarelli E, Melcarne A, Bartoletti-Stella A, Salfi N, Tallini G, Martinuzzi A, Carelli V, Attimonelli M, Rugolo M, Romeo G, Gasparre G. (2010) The genetic and metabolic signature of oncocytic transformation implicates HIF1alpha destabilization. Hum Mol Genet 19(6):1019-32.
11.Gasparre G, Iommarini L, Porcelli AM, Lang M, Ferri GG, Kurelac I, Zuntini R, Mariani E, Pennisi LF, Pasquini E, Pasquinelli G, Ghelli A, Bonora E, Ceccarelli C, Rugolo M, Salfi N, Romeo G, Carelli V. (2009) An inherited mitochondrial DNA disruptive mutation shifts to homoplasmy in oncocytic tumor cells. Hum Mutat 30(3):391-6.
12.Porcelli AM, Ghelli A, Iommarini L, Mariani E, Hoque M, Zanna C, Gasparre G, Rugolo M. (2008) The antioxidant function of Bcl-2 preserves cytoskeletal stability of cells with defective respiratory complex I. Cell Mol Life Sci 65(18):2943-51.
13.Lascaro D, Castellana S, Gasparre G, Romeo G, Saccone C, Attimonelli M. (2008) The RHNumtS compilation: features and bioinformatics approaches to locate and quantify Human NumtS. BMC Genomics 9:267.
14.Gasparre G, Hervouet E, de Laplanche E, Demont J, Pennisi LF, Colombel M, Mège-Lechevallier F, Scoazec JY, Bonora E, Smeets R, Smeitink J, Lazar V, Lespinasse J, Giraud S, Godinot C, Romeo G, Simonnet H. (2008) Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I deficiency in the benign renal oncocytoma. Hum Mol Genet 17(7):986-95.
15.Gasparre G, Porcelli AM, Bonora E, Pennisi LF, Toller M, Iommarini L, Ghelli A, Moretti M, Betts CM, Martinelli GN, Ceroni AR, Curcio F, Carelli V, Rugolo M, Tallini G, Romeo G. (2007) Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc Natl Acad Sci U S A. 104(21):9001-6.
16.Bonora E, Porcelli AM, Gasparre G, Biondi A, Ghelli A, Carelli V, Baracca A, Tallini G, Martinuzzi A, Lenaz G, Rugolo M, Romeo G. (2006) Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. Cancer Res 66(12):6087-96.
17.Stankov K, Biondi A, D'Aurelio M, Gasparre G, Falasca A, Romeo G, Lenaz G. (2006) Mitochondrial activities of a cell line derived from thyroid Hürthle cell tumors. Thyroid 16(4):325-31.

Project Title: